For research use only. Not for therapeutic Use.
ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant[1][2][3].
ODN 1585 (3 μg/mL, 48 h) induces PBMC producing IFN-α in the nanogram range[3].
ODN 1585 increases the percentage of CD69+ (early marker of activation) NK cells within 24 h (26±7%)[3].
CpG ODN (0.6μg/mL, 18 h) stimulates NK cell-mediated lysis of K562 cells[3].
ODN 1585 (50-500 μg, Injection into the tibialis anterior muscle, single) protects 20 to 90% of mice from sporozoite infection[1].
ODN 1585 (100 μg/dose, IP, twice weekly) is determined to be optimal for the induction of antitumor responses in several systems involving comparisons of 30, 100, and 300 μg/injection[2].
| Catalog Number | I043319 |
| CAS Number | 386832-46-8 |
| Purity | ≥95% |
| Reference | [1]. Gramzinski RA, et al. Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun. 2001 Mar;69(3):1643-9. [2]. Blazar BR, et al. Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blood. 2001 Aug 15;98(4):1217-25. [3]. Krug A, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol. 2001 Jul;31(7):2154-63. |
